All News
FORWARD databank RA
4500+ opioid & 11000+ NSAID
MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 PY)
Deaths 95 vs. 228 (12.6/1000 PY vs. 8.2/1000 PY)
IR MACE & mortality NSAID < Opioids
Driven by VTE > Opioids vs NSAIDs HR=2.45
https://t.co/fl7cJNGrvu
Abs#1646 #ACR22 @Rheumnow https://t.co/wV5hYMfYLl
Aurelie Najm AurelieRheumo ( View Tweet)
Brooks et al. Risk lung cancer higher in RA (aHR 1.53) and RA-ILD (aHR 3.06) than controls. Persisted in non-smokers, non-RA-ILD, incident RA @RheumNow #ACR22 Abstr#1647 #ACRbest https://t.co/c18k9OLDIm https://t.co/UTgYZAmfmk
Richard Conway RichardPAConway ( View Tweet)
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
Treatment algorithms for GIO and in special populations (age < 18) @rheumnow https://t.co/dZ02kuOUeH
TheDaoIndex KDAO2011 ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. <75 HR 4.8 . ILD first HR 8.4 @RheumNow #ACR22 Abstr#1959 #ACRbest https://t.co/mnbeBPuyC7 https://t.co/sLU2ZuTMw7
Richard Conway RichardPAConway ( View Tweet)
Of course, imaging itself can be useful in PMR in many situations - and, like GCA, there are merits to all of ultrasound, MRI, and PET/CT.
Nice summary slide @drceowen #ACR22 @RheumNow https://t.co/1LO3DvW7tm
David Liew drdavidliew ( View Tweet)
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Special pops recs for:
Organ transplant - against romosozumab (CVD risk)
Women of child bearing age (not planning) - BIS/TERI
Children - Vit D/Ca unless Fx
Very high doses: more aggressive
@RheumNow https://t.co/xY7Yc3BANj
Eric Dein ericdeinmd ( View Tweet)
Paul Emery presenting phase 2 data Peresolimab in RA. Novel mechanism aiming to restore immune homeostasis. Exciting for rheumatic disease beyond RA.
@RheumNow #ACR22 #LateBreaking https://t.co/oOjvo5YmDB
Julian Segan JulianSegan ( View Tweet)
Tam et al . Increased CV risk in early RA abrogated with treat to target approach. @RheumNow #ACR22 Abstr#1649 https://t.co/i2iHyPoKf0 https://t.co/u0R00oolyP
Richard Conway RichardPAConway ( View Tweet)
Reproductive concerns of adolescent patients with rheumatic disease
Abstract #129 #ACR22 @RheumNow
🤰Worried about effects of dx and meds on fertility and pregnancy
💊Concerns about which birth control to use
🩸Effects of dx. on menstruation
Catherine Sims, MD DrCassySims ( View Tweet)
Kimbrough et al. Comorbidities assoc serious infection in RA. Many! 26/55 comorbidities assoc serious infection. Number of comorbidities also assoc HR 1.16 (1.13-1.19) @RheumNow #ACR22 Abstr#1950 https://t.co/gnIlaJ037B https://t.co/6SR2Ej584w
Richard Conway RichardPAConway ( View Tweet)
RA asso w/ higher risk of lung cancer aHR 1.53, also in non-smokers aHR 1.66 🚬
Now this risk increases even more in pts w/ RA-ILD 🫁
aHR 3.06
No adjustment on occupation or non tobacco inhaled toxic exposure
https://t.co/41ibPD6S3b
Abs#1647 #ACR22 @RheumNow https://t.co/LNw792MYV0
Aurelie Najm AurelieRheumo ( View Tweet)
Does Evusheld shield people living with rheumatic diseases? #ACR22
https://t.co/IutdoFxJUx https://t.co/FuKZEtpImm
Links:
Dr. John Cush RheumNow ( View Tweet)
#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1
Olga Petryna DrPetryna ( View Tweet)
Yazici et al. IA Lorecivivint in Knee OA. 56 week DB-RCT of single injection at time 0. Didn't work. Not for primary endpoint (Pain NRS) or any PRO. @RheumNow #ACR22 Abstr#1639 https://t.co/66KyJW1zVz
Richard Conway RichardPAConway ( View Tweet)
Ultrasound and MRI have taught us a lot about PMR, but it's the power of PET/CT which illustrated the specific pathology of PMR in full color vision.
@drceowen #ACR22 @RheumNow https://t.co/N8hVjqpVwe
David Liew drdavidliew ( View Tweet)
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Initial Fracture Risk Assessment - by age - remember: no FRAX scores <40 yo
Fracture re-assessments every 1-2 years with repeat BMD and risk stratifications
@RheumNow https://t.co/QlCVM1lDb0
Eric Dein ericdeinmd ( View Tweet)
BE OPTIMAL: BKZ in PsA Phase 3 RCT
Data at 52 wks 700+ completed study
ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA
PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA
No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA
Candida infections 7% BKZ, 0.7% ADA
https://t.co/MMjN1Aa3qf
Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
in patients under 40 yo, you cannot calculate #FRAX score, assess BMD and in children get also thoracolumbar xrays. Get repeat testing every 1-2 years #ACR22 @rheumnow https://t.co/CgsvzGKYuV
TheDaoIndex KDAO2011 ( View Tweet)
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM
Janet Pope Janetbirdope ( View Tweet)
800+ women w/ IMID & 1700+ ctrl w/ 6 yrs follow-up
All GC users < BMD levels
-4.2% > 2.5mg/d
-2.7% <2.5mg/d
Crude FX rate 4.8/100PY GC >= 5mg/d, 2.5/100PY GC < 2.5mg/d
🦴Fx incidence > IMID vs. Ctrls
GC use >= 5mg/d x2 risk of Fx
https://t.co/6sj77PwyYQ
Abs#L01 #ACR22 @Rheumnow https://t.co/OZhfuh0Jrm
Aurelie Najm AurelieRheumo ( View Tweet)